We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksByotrol Regulatory News (BYOT)

Share Price Information for Byotrol (BYOT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.10
Bid: 0.05
Ask: 0.15
Change: -0.025 (-20.00%)
Spread: 0.10 (200.00%)
Open: 0.125
High: 0.125
Low: 0.075
Prev. Close: 0.125
BYOT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

30 Jan 2020 17:00

RNS Number : 4897B
Byotrol PLC
30 January 2020
 

 

 

Byotrol plc

("Byotrol", the "Company" or the "Group")

 

Director/PDMR Shareholding

 

 

Byotrol Plc (AIM:BYOT), the anti-microbial technology company, announces that on 30 January 2020, John Langlands, Non-Executive Chairman of the Company, and Nic Hellyer, Chief Financial Officer of the Company, purchased 1,000,000 and 500,000 ordinary shares of 0.25p each ("Ordinary Shares") respectively at prices between 1.79 and 1.83 pence per Ordinary Share, respectively (the "Purchases").

Following the Purchases, Mr. Langlands has an interest in 9,000,000 Ordinary Shares representing approximately 2.04 per cent. of the total voting rights of the Company and Nic Hellyer has an interest in 500,000 Ordinary Shares representing approximately 0.11 per cent. of the total voting rights of the Company.

 

 

 

Enquiries:

David Traynor - Chief Executive, Byotrol plc 01925 742 000

David Paton - Investor Relations 07714 190 474

finnCap Ltd 020 7110 0500(NominateAdviser & Broker)

Geoff Nash/Teddy Whiley Corporate Finance

Richard Chambers - Corporate Broking

 

The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.

 

 

Noteto Editors: 

Byotrol plc (BYOT.L), quoted on AIM, is a specialist developer of antimicrobial technologies, identifying, developing, formulating and commercialising cutting-edge antimicrobial solutions.

Our patented suite of technologies delivers powerful, broad-spectrum efficacy, optimised against commonly-occurring and industry-specific pathogens.

Founded in 2005, the Company seeks to develop and commercialise advanced antimicrobial technologies that create easier, safer and cleaner lives for everyone.

For more information, please go to www.byotrol.co.uk

 

 

Accordingly, the Company makes the following announcement and notification in accordance with the EU Market Abuse Regulation (No 596/2014):

 

1.

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

John Langlands

2.

Reason for the Notification

a)

Position/status

Non-Executive Chairman

b)

Initial notification/Amendment

Initial

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Byotrol Plc

b)

LEI

213800AJMTSTIPA59A34

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

ordinary shares of 0.25p each

Identification code

GB00B0999995

b)

Nature of the transaction

Purchase of Ordinary Shares

c)

Price(s) and volume(s)

Volume - 250,000

Price - 1.7975 pence

Volume - 500,000

Price - 1.83 pence

Volume - 250,000

Price - 1.79 pence

d)

Aggregated information:

Volume - 1,000,000

Aggregated price - 1.81 pence

e)

Date of the transaction

30 January 2020

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

 

1.

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Nic Hellyer

2.

Reason for the Notification

a)

Position/status

Chief Financial Officer

b)

Initial notification/Amendment

Initial

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Byotrol Plc

b)

LEI

213800AJMTSTIPA59A34

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

ordinary shares of 0.25p each

Identification code

GB00B0999995

b)

Nature of the transaction

Purchase of Ordinary Shares

c)

Price(s) and volume(s)

Volume - 278,164

Price - 1.7975 pence

Volume - 221,836

Price - 1.799 pence

d)

Aggregated information:

Volume - 500,000

Aggregated Price - 1.798 pence

e)

Date of the transaction

30 January 2020

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHDZGFMVGRGGZM
Date   Source Headline
15th Apr 202411:48 amRNSHolding(s) in Company
8th Apr 20247:00 amRNSHolding(s) in Company
2nd Apr 20243:27 pmRNSDirector Dealing
28th Mar 20247:00 amRNSProposed Cancellation
22nd Dec 202311:44 amRNSHolding(s) in Company
7th Dec 20237:00 amRNSHalf-year Report
14th Nov 20237:00 amRNSLaunch of PROCESSUS® Instrument Decontamination
14th Nov 20237:00 amRNSTrading Update
9th Nov 20233:43 pmRNSHolding(s) in Company
27th Sep 20237:00 amRNSBoard Changes
13th Sep 20233:33 pmRNSResult of AGM
8th Sep 20234:33 pmRNSDirector Dealing
7th Sep 20237:01 amRNSBoard Appointment
7th Sep 20237:00 amRNSTrading Update
29th Aug 20238:51 amRNSLaunch of CHEMGENE MEDLAB into human healthcare
23rd Aug 20237:00 amRNSInvestor Presentation via Investor Meet Company
31st Jul 20237:00 amRNSFinal Results
6th Jul 20237:00 amRNSPatent Grant for Novel Anti-viral Seaweed Extract
24th May 20233:14 pmRNSUS EPA approves Byotrol24 as long-lasting virucide
24th May 20238:51 amRNSDirector Dealing
28th Apr 20239:57 amRNSDirector Dealing
27th Apr 20237:00 amRNSTrading Update and Board Changes
1st Feb 20239:52 amRNSDirector Dealing
22nd Dec 20223:08 pmRNSDirector Dealing
19th Dec 202210:00 amRNSDirector Dealing
16th Dec 20227:00 amRNSGrant of Share Incentive Awards
12th Dec 20227:00 amRNSInterim results and Investor Presentation
22nd Nov 20227:00 amRNSDirectorate Changes
27th Sep 202211:15 amRNSPDMR Shareholding
22nd Sep 20225:21 pmRNSResult of AGM
8th Sep 20227:00 amRNSDirector Dealing
2nd Sep 202210:02 amRNSInvestor Presentation
30th Aug 20227:00 amRNSFinal Results
12th Aug 20223:30 pmRNSDirector Dealing
28th Jul 20227:00 amRNSCompletion of Convertible Loan Note Fundraising
11th Jul 20227:00 amRNSTrading Update and Notice of Results
22nd Apr 20229:14 amRNSHolding(s) in Company
2nd Mar 20227:00 amRNSTrading Update
12th Jan 20227:00 amRNSSenior Management Appointment
14th Dec 20219:06 amRNSSecond Price Monitoring Extn
14th Dec 20219:00 amRNSPrice Monitoring Extension
13th Dec 20217:00 amRNSDirectorate Change
9th Dec 20218:51 amRNSDirector Dealing
8th Dec 20217:00 amRNSInterim Results and Investor Presentation
2nd Nov 20217:00 amRNSDirectorate and Senior Management Changes
1st Nov 202111:36 amRNSTotal Voting Rights
1st Nov 202111:20 amRNSHolding(s) in Company
28th Oct 202111:40 amRNSExercise of Options & Total Voting Rights
20th Oct 20214:46 pmRNSResult of AGM
1st Oct 20217:00 amRNSSale of Byotrol24 in the Americas

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.